A new screening study has shown that three natural compounds present in foods like green tea may be candidates for drugs that combat the coronavirus.
List view / Grid view
Researchers have made a respiratory model of COVID-19, made from patient-derived stem cells, to understand how the virus affects respiration and which could be used to test possible drugs.
Researchers at UC Davis Health have engineered an antibody that interferes with a critical cell mechanism to reduce transmission of the virus that causes COVID-19 in lab tests.
Using virtual screening, researchers have discovered several natural compounds that could inhibit the SARS-CoV-2 main protease.
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
In murine models of COVID-19, researchers found that non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the inflammatory response and production of antibodies.
Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.
Researchers found that SARS-CoV-2 persists in the brain after it is cleared in the lungs and concluded the severest and longest lasting symptoms of COVID-19 may be caused by brain infection.